Wednesday, 25 Apr 2018

You are here

The RheumNow Week in Review - 16 March 2018

Dr. Jack Cush reviews the highlights from the news, journals and major meetings.  Bigtime rheumatologic lessons with tales from intestinal crypts, the friendly skies & the hips of hockey players. Also the microbiome and lupus, benefits of ENT findings with GPA and rare risk of opportunistic infections with biologics.

  1. Metanalysis of checkpoint inhibitor (nivolumab, pembrolizumab or atezolizumab) shows high rates of hypothyroidism (OR 7.6), pneumonitis (5.4), colitis (2.9), hypophysitis (3.4), rash (2.4), fatigue (32%), diarrhea (19%) and  a >20% frequency of arthraligia or back pain. https://t.co/1WMuRRCWZN
  2. Science Translocation of a gut microbe, Enterococcus gallinarum to tissues triggers autoimmunity in mice with a genetic predispositon to lupus. Vancomycin prevented mortality by suppressing E. gallinarum and eliminating pathogenic autoantibodies and T cells. https://t.co/02vZstzQ86
  3. An Italian 89 pt GPA study finds ENT involvement in 72%; they tend to be younger with less renal disease. Sinonasal symptoms were seen in 58% and otitis media/otomastoiditis in 35%. ENT involvement predicted better outcomes and milder GPA with risk of lower renal disease and mortality rate. https://t.co/UWjzzloxm9
  4. Comparing patients who travel by air vs. those by land to/from hospital after TKR, THR, finds 3 fold higher rates of venous thromboembolic events (VTE) (1.64% vs 0.58%) https://t.co/n5cu9eeqz6
  5. Opportunistic Infections in RA Rare with Biologics   
  6. Bone Marrow Edema Found in SI Joint of Athletes  
  7. Plaquenil During Lupus Pregnancy Lessens Flares 
  8. CARES Study- More CV Deaths with Febuxostat 

“A goal without a plan is just a wish.” ― Antoine de Saint-Exupéry (goals specific, measureable, attainable, realistic & timely - Christine Bundy)

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Rheumatologists' Comments

Many gout patients placed on febuxostat due to renal diseases. Could presence kidney problems raise risk adverse cardiovascular events for those on febuxostat?

More Like This

The RheumNow Week in Review – Vitamin D Snark Report (4.20.18)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.  A second life for Syk kinase, Vitamin D talk, VTE, regulatory hearings and the Lupus clinic edge.

RheumNow Week in Review - Do you Dig Shingrix? (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlights includes manpower shortfalls, comorbidities in AA Lupus, certolizumab pregnancy safety, which Shingles vaccine is best and the power of combination biologics in severe refractory  SLE.

"Breakthrough" Drug Designation by the FDA

The current issue of the NEJM reviews the Food and Drug Administration (FDA) “breakthrough therapy” designation that was introduced in 2012 to expedite testing and approval of medications that were intended to treat serious or life-threatening conditions.  This status is granted when preliminary evidence with a new drug suggests substantial benefits over existing therapies for these unfortunate conditions.

ACR Projects Significant Manpower Shortages for 2030

Arthritis & Rheumatology has published the results of the 2015 Workforce Study of Rheumatology Specialists, and estimates a current shortage (demand > supply) of 700 (12.9%) full-time rheumatologists and that this deficit will worsen (102%) to 4133 FTE by 2030.

RheumNow Week in Review -The Temporal Artery Biopsy Letdown (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on the cost of RA care, infections on planes, CV events and Sacroiliitis in IBD, NXP-2 antibodies and calcinosis and rituximab in myositis ILD patients.